TFPI2 suppresses the interaction of TGF-β2 pathway regulators to promote endothelial-mesenchymal transition in diabetic nephropathy

Endothelial-mesenchymal transition (EndMT) is an important source of myofibroblasts, but also contributes to the progression of diabetic nephropathy (DN). By several differential gene expression analyses from the Gene Expression Omnibus (GEO) database, the tissue factor pathway inhibitor 2 (TFPI2) gene, known as a tumor suppressor, was shown to be dysregulated in DN; however, the potential role and regulatory mechanism of TFPI2 in DN are unclear. Here, we found abnormal upregulation of TFPI2 in the renal cortex of diabetic mice, accompanied by impaired renal function. We also injected a single dose of adeno-associated virus (AAV)2 carrying shRNA targeting TFPI2 intravenously into these mice and found that knockdown of TFPI2 improved renal function and reduced renal fibrosis and cell apoptosis in experimental DN. Furthermore, hyperglycemia-induced EndMT was inhibited in the absence of TFPI2, as evidenced by increased expression of endothelial markers (VE-cadherin and CD31) and decreased expression of mesenchymal markers (alpha-SMA, des-min, and FSP-1). To further explore the mechanism in vitro, human renal glomerular endothelial cells (hRGECs) were incubated in the presence of high glucose or transforming growth factor beta (TGF-beta)2. TFPI2 deficiency inhibited high glucose-induced cell apoptosis and TGF-beta 2-induced EndMT in hRGECs, while overexpression of TFPI2 had the opposite effects. Importantly, TGF-beta 2 is a crucial driver of EndMT, and we found that TFPI2 promoted TGF-beta 2/Smad signaling activation by interferring the interaction of TGF-beta pathway regulators (SMURF2 with SMAD7). Our results show that TFPI2 regulates EndMT and the TGF-beta 2 signaling pathway and is a potential promoter of DN pathogenesis.